Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
ID: HT9402-24-Q-9401Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYAURORA, CO, 80011, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/f7d4c75429be45bd8e01372865e0851f/view
Timeline
    Description

    The Department of Defense (DoD) is soliciting quotations for pharmaceutical agents under the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at enhancing the Military Health System's pharmacy benefits. This procurement process is governed by 10 U.S.C. § 1074g and involves the evaluation of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on specific drug classes such as Oral CGRP migraine agents and Interleukin 17 and 23 targeted immunomodulatory biologics. Interested manufacturers must submit their quotes by September 19, 2024, following a pre-quotation teleconference scheduled for July 24, 2024, and can direct inquiries to primary contacts Stephanie Erpelding and Tracy Banks via their provided emails.

    Point(s) of Contact
    Stephanie Erpelding
    stephanie.j.erpelding.civ@health.mil
    Tracy Banks
    tracy.e.banks2.civ@health.mil
    Files
    Title
    Posted
    Amend 0001 November 2024 PT Meeting Reporting.xlsx
    The Pharmacy Operations Support Contract (POSC) outlines the limitations of the Military Health System's Pharmacy Data Transaction Service (PDTS), which is utilized for managing pharmacy-related communications, patient eligibility, and claims processing. The document highlights issues such as the inability to record prescriptions that patients fail to pick up, changes in medication supply durations affecting prescription counts, and challenges in distinguishing between acute and chronic prescriptions. This data is also constrained in research and data mining applications due to its primary focus on patient safety in claims processing. The dataset details specific medications and their classifications, including migraine agents and immunomodulatory biologics, emphasizing the frequency and forms of prescriptions dispensed through various channels, including mail order and Military Treatment Facilities (MTFs). The document mentions the necessity of using Microsoft Excel 2010 for full functionality of the report and establishes a direct connection to the upcoming P&T meeting scheduled for November 2024, covering the reporting period from July 2023 to June 2024. This structure is important for ensuring that stakeholders are aware of ongoing pharmacy operations and the associated data integrity issues within the Military Health System.
    Amend 0002 RFQ HT9402-24-Q-9401.pdf
    The Department of Defense (DoD) seeks quotations for pharmaceutical agents under its Uniform Formulary (UF) initiative, governed by 10 U.S.C. § 1074g. The Defense Health Agency (DHA) aims to integrate effective pharmacy benefits for the Military Health System through the Pharmacy and Therapeutics (P&T) Committee. This RFQ outlines the process for manufacturers to submit price offers for agents based on their clinical and cost effectiveness. The document includes detailed instructions for submitting quotes for Blanket Purchase Agreements (BPAs) and Additional Discount Programs (ADPs), alongside evaluation criteria. Key components include a pre-quotation teleconference, submission deadlines, and a checklist for manufacturers to ensure compliance with requirements. The P&T Committee will evaluate submissions based on relative effectiveness and will classify pharmaceutical agents into cost-sharing tiers. Overall, this RFQ embodies the DoD's commitment to providing efficient pharmacy services while managing costs through strategic partnerships with pharmaceutical manufacturers.
    Amendment 0001.pdf
    The Defense Health Agency has issued an amendment to Solicitation HT9402-24-Q-9401 concerning updates to the November 2024 PT Meeting Reporting document. This amendment specifically adds information regarding Oral CRGP Agents. Importantly, all other terms and conditions of the original solicitation will remain unchanged. The notice was signed by Marsha L. Petersen, the Contracting Officer, on August 14, 2024. This update indicates the agency's ongoing commitment to ensure relevant and accurate documentation for its reporting procedures, emphasizing the importance of informing stakeholders about new developments. Overall, this communication reflects standard protocol in governmental contracting processes.
    Amendment 0002.pdf
    The Defense Health Agency issued an amendment to the Request for Quote (RFQ) HT9402-24-Q-9401, extending the due date for submissions regarding the November 2024 Pharmacy and Therapeutics (P&T) drug classes. The new submission deadline has been revised from September 12, 2024, to September 19, 2024. All other terms and conditions of the RFQ remain unchanged. This modification is formally acknowledged by Marsha L. Petersen, the Contracting Officer, underscoring the agency's procedural adjustments in response to the need for more time for potential bidders. Ensuring thorough participation in the RFQ process is essential for acquiring necessary pharmaceutical supplies and services for defense health operations.
    NDC Price List - Migraine Agents - Oral CGRP.xlsx
    The Department of Defense (DoD) is convening a Pharmacy and Therapeutics (P&T) Committee meeting on November 6-7, 2024, to review migraine agents within the DOD Uniform Formulary, specifically focusing on Oral CGRP medications. Quotes from drug manufacturers are required by September 12, 2024, and no current quotes have been submitted for listed National Drug Codes (NDCs) related to ongoing scenarios. The document specifies two main scenarios: one analyzing up to two agents before step therapy and another assessing agents after step therapy. Special reimbursement programs may be introduced, incentivizing the use of high-value products while discouraging lower-value alternatives. Additionally, the document addresses the requirements for price submission, the necessary prior authorization processes, and potential formulary changes based on cost competitiveness. Notably, all agents not selected for the formulary may be classified as non-step preferred. This document serves as an essential reference for manufacturers wishing to submit quotes and highlights the DoD’s commitment to effective medication management within military healthcare.
    NDC Price List - TIBS - IL 17.xlsx
    The document outlines the agenda and requirements for the upcoming Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee meeting scheduled for November 6-7, 2024, focusing on Targeted Immunomodulatory Biologics, specifically within the subclass of Interleukin 17. Quotes for relevant pharmaceutical agents are due by September 12, 2024. The document includes detailed scenarios for formulary management concerning step therapy and non-formulary agents, emphasizing that prior authorization may be needed for new patients. The P&T Committee may recommend agents for preferential status or exclusion from TRICARE benefits based on their evaluation. Additionally, it discusses the financial framework involving TRICARE retail refunds and annual ceiling prices for pharmaceuticals, highlighting the need for manufacturers to submit completed documentation with their quotes. Overall, the document serves to guide pharmaceutical companies on compliance and participation in the federal formulary process concerning specific medications.
    NDC Price List - TIBS - IL 23.xlsx
    The Department of Defense (DOD) is preparing for a Pharmacy and Therapeutics (P&T) Committee meeting scheduled for November 6-7, 2024, focusing on the subclass of Targeted Immunomodulatory Biologics, specifically Interleukin 23. Bids for participation in this formulary are due by September 12, 2024. The document outlines various scenarios concerning the submission of quotes for drugs related to this subclass, detailing conditions under which these drugs may be categorized as formulary or non-formulary. Key considerations include potential prior authorization requirements and step therapy protocols, which mandate trials of preferred medications before non-preferred options can be administered. Additionally, it emphasizes the committee's flexibility in recommending certain drugs for preferential cost-sharing treatment or exclusion from the TRICARE pharmacy benefits. The document also instructs manufacturers to submit fully executed quotes, which may impact pricing strategies and rebate percentages calculated based on previously established Federal Ceiling Prices (FCP). This document serves as a formal call for quotes, providing manufacturers with the necessary guidelines to participate in the DOD's pharmaceutical procurement process while complying with regulatory and contractual obligations.
    NDC Price List FAQ Class Review.pdf
    The Price Appendix FAQ document outlines essential instructions for submitting pricing information related to the formularies in a government Request for Quotation (RFQ) process. It includes directives for both Blanket Purchase Agreements (BPA) and Acquisition Drug Programs (ADP). Users are advised to read the Formulary Notes to understand the decision-making of the Pharmacy and Therapeutics (P&T) committee. They must fill in designated yellow cells while other cells remain locked, and certain actions, such as submitting a zero additional refund, will visually indicate a lack of interest in a quote. The document provides tables for up to ten National Drug Codes (NDCs) and offers guidelines for those wishing to submit more than ten. The calculations for price per unit and total refunds are automated for user convenience. Overall, the document serves as a crucial guideline for participants in the government procurement process, ensuring compliance with pricing submission protocols.
    November 2024 PT Meeting Reporting.xlsx
    The Pharmacy Operations Support Contract (POSC) document discusses the limitations and functionalities of the Military Health System (MHS) Pharmacy Data Transaction Service (PDTS). This integrated system is used to convey patient eligibility, manage drug interactions, and support pharmacy claim reimbursements across various points of service. However, the report notes significant limitations in utilizing PDTS for research or data mining, including difficulties in tracking prescription compliance, identifying acute vs. chronic use, and understanding off-label medication usage. Changes in dispensing procedures, especially supply limits, could further distort prescription counts. The dataset focuses on the dispensing of specific medication subclasses and emphasizes brand and generic identification at the transaction level. It includes detailed reporting for the Pharmacy and Therapeutics (P&T) meetings covering a one-year date range from July 2023 to June 2024. The summary of the findings illustrates the importance of reliable data for maintaining patient safety and efficiently processing pharmacy claims while highlighting existing challenges impeding comprehensive analysis and oversight.
    RFQ HT9402-24-Q-9401 CR.pdf
    The Department of Defense (DoD) is soliciting quotations for pharmaceutical agents for integration into the Military Health System (MHS) through its Pharmacy and Therapeutics Committee under the Uniform Formulary (UF). This Request for Quotation (RFQ) facilitates the establishment of Blanket Purchase Agreements (BPA) and Additional Discount Programs (ADP) aimed at reducing costs of pharmaceuticals under TRICARE. Manufacturers can submit offers for drugs, which the DoD evaluates based on clinical effectiveness and cost-effectiveness for tier classification. Notable requirements include specific price quotes for different pharmaceutical agents and the potential for refunds based on each agent's market performance. The document also delineates pre-quotation conferences, submission deadlines, and key personnel contacts. Moreover, it emphasizes the importance of adherence to regulatory standards, price validity for 180 days, and the manner in which the DoD will process submissions and evaluate competitive pricing. The goal of these agreements is to ensure that beneficiaries have access to essential medications at an optimal cost while complying with federal regulations governing pharmaceutical procurement.
    Similar Opportunities
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense (DoD) is issuing a Request for Quotation (RFQ) for the establishment of Blanket Purchase Agreements (BPA) and Additional Discount Program (ADP) agreements related to pharmaceutical agents under the Defense Health Agency's Uniform Formulary (UF). This procurement aims to secure pricing agreements for various newly approved drugs, including those in the classes of Parkinson's agents, gastrointestinal agents, respiratory agents, hematological agents, targeted immunomodulatory biologics, anticonvulsants, and oncological agents, which will be reviewed during the Pharmacy and Therapeutics (P&T) Committee meeting scheduled for November 6-7, 2024. The initiative is crucial for maintaining an effective pharmacy benefits program for the Military Health System (MHS), ensuring that military personnel have access to high-value medications while adhering to cost-effectiveness criteria. Interested manufacturers must submit their quotes by September 19, 2024, and can direct inquiries to primary contact Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil or secondary contact Tracy Banks at tracy.e.banks2.civ@health.mil.
    Famotidine
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Doxycycline Hyclate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Dimethyl Fumarate DR capsules. The contract will establish a national supply source for the purchase of these capsules by Department of Defense customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on DLA Bid Board System and Beta Sam.Gov. Interested parties should contact Kevin Rafferty for any questions/comments. The projected solicitation date is February 2021.
    Pantoprazole DR Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Telmisartan Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Telmisartan Tablets. Telmisartan Tablets are pharmaceutical preparations used to treat high blood pressure and reduce the risk of heart attack, stroke, and kidney problems in certain patients. The tablets will be available in 20MG, 40MG, and 80MG strengths, packaged in 30 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide Telmisartan Tablets to Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs customers through the DLA and VA prime vendor programs. Interested parties can contact Courtney Hunter-Stangler at (215) 737-6845 or Courtney.Hunter-Stangler@dla.mil for any questions/comments. The solicitation is projected to be issued in August of 2024.
    Rizatriptan Benzoate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    Repaglinide
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used for treating high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties can contact Catherine Gilbert for more information. The solicitation is projected to be issued in December 2019.
    Rabeprazole Sodium Delayed Release Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.